Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioenvision
Pharma firm reports 65% increase in revenue, provides clinical update
June 15th, 2005
Bioenvision (BIVN) announced financial results for the 3 and 9 months ended March 31, 2005. "We have made considerable progress in developing our product portfolio over the past 12 months and now have multiple products in clinical trials," commented Christopher Wood, MD, chairman and chief executive officer of Bioenvision. "We have submitted a Marketing Authorization Application, the European equivalent of a U.S. New Drug Application, with the European Medicines Evaluation Agency (EMeA) for European approval of clofarabine in relapsed or refractory pediatric acute leukemia. We anticipate an opinion from the EMeA in the third quarter of calendar 2005,...
Source: Physician Law Weekly (2005-06-15)
|
